These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 20682979)

  • 1. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
    Yin M; Yan J; Martinez-Balibrea E; Graziano F; Lenz HJ; Kim HJ; Robert J; Im SA; Wang WS; Etienne-Grimaldi MC; Wei Q
    Clin Cancer Res; 2011 Mar; 17(6):1632-40. PubMed ID: 21278243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XPF-ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer.
    Huang MY; Huang YJ; Cheng TL; Jhang WY; Ke CC; Chen YT; Kuo SH; Lin IL; Huang YH; Chuang CH
    Cells; 2023 May; 12(11):. PubMed ID: 37296596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA-seq identifies determinants of oxaliplatin sensitivity in colorectal cancer cell lines.
    Li XX; Peng JJ; Liang L; Huang LY; Li DW; Shi DB; Zheng HT; Cai SJ
    Int J Clin Exp Pathol; 2014; 7(7):3763-70. PubMed ID: 25120752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.
    Stevenson L; Allen WL; Turkington R; Jithesh PV; Proutski I; Stewart G; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG
    Clin Cancer Res; 2012 Oct; 18(19):5412-26. PubMed ID: 22859720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene network analysis of oxaliplatin-resistant colorectal cancer to target a crucial gene using chitosan/hyaluronic acid/protamine polyplexes containing CRISPR-Cas9.
    Shirani-Bidabadi S; Mirian M; Varshosaz J; Tavazohi N; Sadeghi HMM; Shariati L
    Biochim Biophys Acta Gen Subj; 2023 Aug; 1867(8):130385. PubMed ID: 37230419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between ERCC1 Gene Polymorphism (rs11615) and Colorectal Cancer Susceptibility: A Meta-Analysis of Medical Image Fusion and Safety Applications.
    Liu M; Qiu Z; Yang Q
    Comput Math Methods Med; 2022; 2022():9988513. PubMed ID: 36277013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-33a-5p in small extracellular vesicles as non-invasive biomarker for oxaliplatin sensitivity in human colorectal cancer cells.
    Tanaka S; Hosokawa M; Miyamoto T; Nakagawa A; Haruna M; Ueda K; Iwakawa S; Ogawara KI
    Biochem Biophys Rep; 2021 Jul; 26():100996. PubMed ID: 33898768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin.
    Rao D; Mallick AB; Augustine T; Daroqui C; Jiffry J; Merla A; Chaudhary I; Seetharam R; Sood A; Gajavelli S; Aparo S; Rajdev L; Kaubisch A; Chuy J; Negassa A; Mariadason JM; Maitra R; Goel S
    Oncotarget; 2019 Sep; 10(53):5510-5522. PubMed ID: 31565185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of p38MAPK-mediated excision repair cross-complementation 1 expression on prognosis of patients with non-small cell lung cancer.
    He D; Ma X; Wu Z; Wang Y; Zhao S; Han F; Sun W
    Oncol Lett; 2017 Sep; 14(3):3463-3472. PubMed ID: 28927101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer.
    Modi S; Kir D; Giri B; Majumder K; Arora N; Dudeja V; Banerjee S; Saluja AK
    J Gastrointest Surg; 2016 Jan; 20(1):13-23; discussion 23-4. PubMed ID: 26503259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas.
    Orlandi A; Di Salvatore M; Bagalà C; Basso M; Strippoli A; Plastino F; Calegari MA; Cassano A; Astone A; Barone C
    J Cancer; 2015; 6(1):70-81. PubMed ID: 25553091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Uncaria tomentosa Extract on Apoptosis Triggered by Oxaliplatin Exposure on HT29 Cells.
    de Oliveira LZ; Farias IL; Rigo ML; Glanzner WG; Gonçalves PB; Cadoná FC; Cruz IB; Farias JG; Duarte MM; Franco L; Bertol G; Colpo E; Brites PC; Rocha JB; Leal DB
    Evid Based Complement Alternat Med; 2014; 2014():274786. PubMed ID: 25505920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological evaluation of transdichloridoplatinum(II) complexes with 3- and 4-acetylpyridine in comparison to cisplatin.
    Filipovic L; Arandelovic S; Gligorijevic N; Krivokuca A; Jankovic R; Srdic-Rajic T; Rakic G; Tesic Z; Radulovic S
    Radiol Oncol; 2013; 47(4):346-57. PubMed ID: 24294179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients.
    Muniz VP; Askeland RW; Zhang X; Reed SM; Tompkins VS; Hagen J; McDowell BD; Button A; Smith BJ; Weydert JA; Mezhir JJ; Quelle DE
    Genes Cancer; 2013 Jul; 4(7-8):273-84. PubMed ID: 24167655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double siRNA-targeting of cIAP2 and LIVIN results in synergetic sensitization of HCT-116 cells to oxaliplatin treatment.
    Bavykin AS; Korotaeva AA; Poyarkov SV; Syrtsev AV; Tjulandin SA; Karpukhin AV
    Onco Targets Ther; 2013; 6():1333-40. PubMed ID: 24098083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells.
    Flamant L; Roegiers E; Pierre M; Hayez A; Sterpin C; De Backer O; Arnould T; Poumay Y; Michiels C
    BMC Cancer; 2012 Sep; 12():391. PubMed ID: 22954140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.
    Gordon MA; Zhang W; Yang D; Iqbal S; El-Khouiery A; Nagashima F; Lurje G; Labonte M; Wilson P; Sherrod A; Ladner RD; Lenz HJ
    Pharmacogenomics; 2011 Jan; 12(1):27-39. PubMed ID: 21174620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
    Seetharam RN; Sood A; Basu-Mallick A; Augenlicht LH; Mariadason JM; Goel S
    Anticancer Res; 2010 Jul; 30(7):2531-8. PubMed ID: 20682979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents.
    Youn CK; Kim MH; Cho HJ; Kim HB; Chang IY; Chung MH; You HJ
    Cancer Res; 2004 Jul; 64(14):4849-57. PubMed ID: 15256455
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.